Research and Clinical Trials

Title  
Merck MK-3475-426: A Phase III Randomized, Open Label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First Line Treatment for Locally Advanced or Metastatic Renal Cell Carci
Brief Description  
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review To evaluate and compare OS in subjects treated with pembrolizumab plus axitinib versus sunitinib monotherapy.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Kidney
Status  
OPEN
Start Date  
02/17/2017
IRB Number  
00019703
Principal Investigator  
Amin, Asim
Contact Name  
Ashley Franklin

For More Information, Contact  Ashley  , Franklin
Phone:  980-442-2315 Fax:    
Email:  Ashley.Franklin@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close